Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4NETWORK 3INDUSTRY 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1

Conditions

Neoplasm Metastasis 2Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Specimen Handling 322Magnetic Resonance Spectroscopy 219Biopsy 186Nivolumab 50X-Rays 45Radiation 42Immunoglobulin G 42Disulfides 42Paclitaxel 40pembrolizumab 39Taxes 39Cyclophosphamide 39Cisplatin 39Platinum 371,2-diaminocyclohexaneplatinum II citrate 37Carboplatin 36Radiotherapy 33atezolizumab 30Doxorubicin 30olaparib 25Gemcitabine 25venetoclax 24Ipilimumab 24CTLA-4 Antigen 24Bevacizumab 24Prednisone 22Vincristine 21Phantoms, Imaging 21cabozantinib 20durvalumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Panitumumab × 30 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05638295 2026-05-13

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
105 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡